AlzBiomarker
MCI-AD vs MCI-Stable: Aβ40 (Plasma)
Meta-analysis Results: Baseline levels of Aβ40 in the plasma did not differ between people with mild cognitive impairment who went on to develop Alzheimer’s dementia and those who had not declined at follow-up. The meta-analysis found nearly equivalent levels between the two groups, although it is limited to three eligible studies (effect size = 1.066, p = 0.00020).

